Literature DB >> 26201022

Involvement of pro-inflammatory cytokines and growth factors in the pathogenesis of Dupuytren's contracture: a novel target for a possible future therapeutic strategy?

Enrica Bianchi1, Samanta Taurone1, Lia Bardella2, Alberto Signore3, Elena Pompili4, Vincenzo Sessa5, Caterina Chiappetta6, Lorenzo Fumagalli4, Cira Di Gioia7, Francesco S Pastore8, Susanna Scarpa9, Marco Artico10.   

Abstract

Dupuytren's contracture (DC) is a benign fibro-proliferative disease of the hand causing fibrotic nodules and fascial cords which determine debilitating contracture and deformities of fingers and hands. The present study was designed to characterize pro-inflammatory cytokines and growth factors involved in the pathogenesis, progression and recurrence of this disease, in order to find novel targets for alternative therapies and strategies in controlling DC. The expression of pro-inflammatory cytokines and of growth factors was detected by immunohistochemistry in fibrotic nodules and normal palmar fascia resected respectively from patients affected by DC and carpal tunnel syndrome (CTS; as negative controls). Reverse transcription (RT)-PCR analysis and immunofluorescence were performed to quantify the expression of transforming growth factor (TGF)-β1, interleukin (IL)-1β and vascular endothelial growth factor (VEGF) by primary cultures of myofibroblasts and fibroblasts isolated from Dupuytren's nodules. Histological analysis showed high cellularity and high proliferation rate in Dupuytren's tissue, together with the presence of myofibroblastic isotypes; immunohistochemical staining for macrophages was completely negative. In addition, a strong expression of TGF-β1, IL-1β and VEGF was evident in the extracellular matrix and in the cytoplasm of fibroblasts and myofibroblasts in Dupuytren's nodular tissues, as compared with control tissues. These results were confirmed by RT-PCR and by immunofluorescence in pathological and normal primary cell cultures. These preliminary observations suggest that TGF-β1, IL-1β and VEGF may be considered potential therapeutic targets in the treatment of Dupuytren's disease (DD).
© 2015 Authors; published by Portland Press Limited.

Entities:  

Keywords:  Dupuytren's contracture; cytokines; growth factors; immunohistochemistry (IHC); myofibroblasts

Mesh:

Substances:

Year:  2015        PMID: 26201022     DOI: 10.1042/CS20150088

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  10 in total

1.  GLYCOSAMINOGLYCANS AND PROTEOGLYCANS IN PALMAR FASCIA OF PATIENTS WITH DUPUYTREN.

Authors:  Priscilla Carneiro Hirai Nascimento; Elsa Yoko Kobayashi; Luiz Guilherme de Saboya Lenzi; João Baptista Gomes Dos Santos; Helena Bonciani Nader; Flávio Faloppa
Journal:  Acta Ortop Bras       Date:  2016 Mar-Apr       Impact factor: 0.513

Review 2.  Current progress in understanding the molecular pathogenesis of burn scar contracture.

Authors:  Jianglin Tan; Jun Wu
Journal:  Burns Trauma       Date:  2017-05-22

Review 3.  Recent advances in the understanding of Dupuytren's disease.

Authors:  Thomas Layton; Jagdeep Nanchahal
Journal:  F1000Res       Date:  2019-02-28

Review 4.  Molecular Aspects of Regional Pain Syndrome.

Authors:  Manuela Baronio; Hajra Sadia; Stefano Paolacci; Domenico Prestamburgo; Danilo Miotti; Vittorio A Guardamagna; Giuseppe Natalini; Stephanie G B Sullivan; Matteo Bertelli
Journal:  Pain Res Manag       Date:  2020-04-11       Impact factor: 3.037

5.  How to Treat Algodystrophy and Rheumatic Comorbidity in Myelofibrosis: Three Case Reports.

Authors:  Olga Magazzino; Tiziana Urbano; Salvatore Magnasco
Journal:  Cureus       Date:  2022-08-16

Review 6.  Connective Tissue Degeneration: Mechanisms of Palmar Fascia Degeneration (Dupuytren's Disease).

Authors:  S Karkampouna; M Kreulen; M C Obdeijn; P Kloen; A L Dorjée; F Rivellese; A Chojnowski; I Clark; Marianna Kruithof-de Julio
Journal:  Curr Mol Biol Rep       Date:  2016-07-14

Review 7.  Basics of Radiation Biology When Treating Hyperproliferative Benign Diseases.

Authors:  Franz Rödel; Claudia Fournier; Julia Wiedemann; Felicitas Merz; Udo S Gaipl; Benjamin Frey; Ludwig Keilholz; M Heinrich Seegenschmiedt; Claus Rödel; Stephanie Hehlgans
Journal:  Front Immunol       Date:  2017-05-03       Impact factor: 7.561

8.  Complex regional pain syndrome-up-to-date.

Authors:  Frank Birklein; Violeta Dimova
Journal:  Pain Rep       Date:  2017-10-05

9.  Attenuation of Dupuytren's fibrosis via targeting of the STAT1 modulated IL-13Rα1 response.

Authors:  Moeed Akbar; Emma Garcia-Melchor; Sabarinadh Chilaka; Kevin J Little; Shatakshi Sood; James H Reilly; Foo Y Liew; Iain B McInnes; Neal L Millar
Journal:  Sci Adv       Date:  2020-07-10       Impact factor: 14.136

10.  Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype.

Authors:  Giulia Stazi; Ludovica Taglieri; Alice Nicolai; Annalisa Romanelli; Rossella Fioravanti; Stefania Morrone; Manuela Sabatino; Rino Ragno; Samanta Taurone; Marcella Nebbioso; Raffaella Carletti; Marco Artico; Sergio Valente; Susanna Scarpa; Antonello Mai
Journal:  Clin Epigenetics       Date:  2019-12-02       Impact factor: 6.551

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.